ReviewPathogens (Basel, Switzerland)2021
Review in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Diagnostic Challenges of Non-Sporulating Fungal Isolates Recovered from Traumatic Wounds Following Motor Vehicle Collisions:Journal of fungi (Basel, Switzerland) · 2026Article
- Article
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
- First Case of Cutaneous Coinfection withDiagnostics (Basel, Switzerland) · 2026Article
- Probable pyoderma gangrenosum complicated with cutaneousFrontiers in medicine · 2026Article
- Essential oils as nature-engineered antifungals: a comprehensive review of pharmacological mechanisms, drug synergism, and advanced formulation strategies.Frontiers in pharmacology · 2026Review
- Primary Cutaneous Aspergillosis Due toInfection and drug resistance · 2026Article
- Correlation between MIC of econazole nitrate and clinical response in otomycosis.Frontiers in cellular and infection microbiology · 2026Article
- Molecular Characterisation of Fungi Populations in the Chronic Wounds of Filarial Lymphedema Patients in Southern Ghana: A Cross-Sectional Study.Health science reports · 2025Article
- Mycogenic Silver Nanoparticles: Promising Antimicrobials with Fungistatic Properties.International journal of molecular sciences · 2025Article
- The Effect of Temperature over the Growth and Biofilm Formation of the ThermotolerantJournal of fungi (Basel, Switzerland) · 2025Article
- Alginate Extracted fromPolymers · 2024Article
- Atypical and Unpredictable Superficial Mycosis Presentations: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2024Review
- Pathogenic Aspergillus Strains Identification and Antifungal Susceptibility Analysis of 452 Cases with Otomycosis in Jingzhou, China.Mycopathologia · 2024Article
- Aspergillus infections of lateral skull base: a case series.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Observational
- Hand contamination and hand hygiene knowledge and practices among commercial transport users after the SARS-CoV-2 virus (COVID-19) scare, Enugu State, Nigeria.PLOS global public health · 2024Article
- Surveillance of Amphotericin B and Azole Resistance inJournal of fungi (Basel, Switzerland) · 2023Article
- In Vitro Antifungal Activity of Selected Essential Oils against Drug-Resistant ClinicalMolecules (Basel, Switzerland) · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superficial and cutaneous aspergillosis is a rare fungal disease that is restricted to the outer layers of the skin, nails, and the outer auditory canal, infrequently invading the deeper tissue and viscera, particularly in immunocompromised patients. These mycoses are acquired through two main routes: direct traumatic inoculation or inhalation of airborne fungal spores into paranasal sinuses and lungs. Lesions are classified into three categories: otomycosis, onychomycosis, and cutaneous aspergillosis. Superficial and cutaneous aspergillosis occurs less frequently and therefore remains poorly characterized; it usually involves sites of superficial trauma-namely, at or near intravenous entry catheter site, at the point of traumatic inoculation (orthopaedic inoculation, ear-self-cleaning, schizophrenic ear self-injuries), at surgery incision, and at the site of contact with occlusive dressings, especially in burn patients. Onychomycosis and otomycosis are more seen in immunocompetent patients, while cutaneous aspergillosis is widely described among the immunocompromised individuals. This paper is a review of related literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.